Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A445 (Gimistotug) with tislelizumab in advanced solid tumors
NCT04215978Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jan 2020
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of gimistotug in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (5 arms), sponsored by BeiGene. Primary endpoints: Adverse Events, Serious Adverse Events and 4 more. Started Jan 2020; status: completed.
02
Drugs
gimistotug
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04215978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215978.